Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, NY 10065, USA.
Semin Oncol. 2011 Oct;38(5):613-20. doi: 10.1053/j.seminoncol.2011.04.013.
Myelodysplastic syndromes (MDS) are a group of clonal hematopoetic disorders marked by ineffective hematopoiesis, peripheral cytopenias, and an increased risk of transformation to acute myeloid leukemia. Multiple processes govern hematopoietic progenitor proliferation and natural differentiation into mature myeloid elements. Molecular events that disrupt any of these processes have the potential to lead to ineffective hematopoiesis and an MDS phenotype. Recent advances in genomic analysis have identified a number of new genes that may be involved. The molecular description of MDS will lead to better understanding, classification, and treatment of this disease.
骨髓增生异常综合征（MDS）是一组克隆性造血疾病，其特征为无效造血、外周血细胞减少以及向急性髓系白血病转化的风险增加。多种过程控制造血祖细胞的增殖和自然分化为成熟髓系细胞。破坏这些过程中的任何一个过程的分子事件都有可能导致无效造血和 MDS 表型。基因组分析的最新进展已经确定了一些可能涉及的新基因。MDS 的分子描述将导致对这种疾病的更好理解、分类和治疗。
